Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Bevacizumab × Other solid neoplasm × Clear all

Phase

Phase 1 29 Phase 1/2 15 Phase 2 10 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 20 Thoracic 7 Gynecologic 4 CNS 3 Other solid neoplasm 1 NET 1 Head & Neck 1 Endocrine 1 Breast 1

Conditions

Interventions

Pemetrexed 4 Cisplatin 4 pembrolizumab 3 Drug Therapy 2 Carboplatin 2 toripalimab 1 tislelizumab 1 spartalizumab 1 sintilimab 1 penpulimab 1 nintedanib 1 camrelizumab 1 balstilimab 1 atezolizumab 1 anlotinib 1 Vincristine 1 Topotecan 1 Sentinel Lymph Node Biopsy 1 Platinum Compounds 1 Melphalan 1 Inosine 1 Injections 1 Indocyanine Green 1 Immunotherapy 1 Hyperthermia, Induced 1 Etoposide 1 Cryotherapy 1 Bevacizumab 1 ADI PEG20 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00651456 2023-03-13

MAPS

Intergroupe Francophone de Cancerologie Thoracique

Phase 2/3 Completed

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡